Arc­tic Vi­sion col­lects $100M to bring US eye dis­ease can­di­dates over­seas

With three eye dis­ease can­di­dates, in-li­censed from the US, Shang­hai-based Arc­tic Vi­sion has hooked more than $100 mil­lion to see the ther­a­pies to the Chi­nese mar­ket — and pos­si­bly be­yond, if CEO Ed­dy Wu gets his way.

Wu took the wraps off a Se­ries B round Wednes­day evening, just sev­er­al months af­ter un­veil­ing a $32 mil­lion A round. The new funds will be used to de­vel­op three can­di­dates li­censed from Clear­side Bio­med­ical and Eye­n­ovia (one of which was slapped with a CRL back in 2019), and ex­tend the com­pa­ny’s reach to oth­er parts of Asia, he said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER